Zepto® receives award for Best Capsulotomy Technology 2017

Zepto® is an easy to use, disposable instrument that provides quick, consistent, and high quality automated capsulotomies that can be personalized for the patient's individual visual axis in routine, challenging and premium cases of cataract surgery.

FREMONT, Calif. (PRWEB) January 18, 2018

Mynosys Cellular Devices Inc. (Fremont, CA. USA) is pleased to announce that its flagship automated capsulotomy device, Zepto®, has been selected as the best capsulotomy technology by Cataract and Refractive Surgery Today, a leading publication that monitors and reviews technology and trends in cataract surgery.

Chief Medical Editor of CRST, Steven J. Dell, MD, of Austin, Texas commented that "The ability to create quick and reliable capsulotomies, even in dense lenses with limited visibility, is an attractive feature of this promising technology." Editorial board member Vance Thompson, MD, of Sioux Falls, South Dakota, called Zepto® "amazing." "This technology allows cataract surgeons to automatically create a perfectly circular capsulotomy that for the first time can be precisely centered on the patient's visual axis to anchor surgery for potentially the best outcome."

Zepto® has received an extremely enthusiastic welcome by cataract surgeons, according to John Hendrick, President & CEO of Mynosys. "Since its international launch in early 2017 and in the US in October 2017, Zepto® has very quickly established itself to be the 'go to' instrument in challenging cases, and is also increasingly used by surgeons to perform personalized cataract procedures whereby a Zepto®-guided, visually centered capsulotomy can anchor the surgery to the patient's individual visual axis". Hendrick adds, "The feedback from surgeons, no matter in hospital-based settings or in high volume premium practices has uniformly been: "Accuracy & strength at another level", "A feeling of achievement" "Increases my efficiency", and 'Wow".

Zepto® is CE Marked and FDA cleared. It is available through distributors in selected countries internationally and in the United States.

Contact; Dr. Pat Lydon
PLydon(at)Mynosys(dot)com

Research was supported by the National Eye Institute / National Institutes of Health under award no. R44EY021023. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH.

Contact Information

John Hendrick
Mynosys Cellular Devices, Inc.
http://www.mynosys.com
+1 510-770-9296